Browse the evidence

Current clinical candidates, including GSBR-1290, CT-996, and ECC5004, offer substantial potential due to their oral bioavailability and favorable gastrointestinal tolerability.

Practitioners may consider these candidates for their potential benefits in treatment regimens.

Obesity is projected to affect 3.8 billion people worldwide by 2050.

Practitioners should be aware of the increasing obesity trend and its implications for health.

There is a complex and bidirectional relationship between adipose and breast tissues.

Understanding this relationship can help in developing targeted interventions for breast cancer.

The global prevalence of obesity has risen sharply during the past half-century, reaching pandemic proportions.

Clinicians should be aware of the increasing obesity rates as a public health concern.

Conventional drug therapies explored in OSA have generally produced disappointing results.

Practitioners should be aware that current drug therapies for OSA may not be effective.

GLP-1RAs probably have little or no effect on risk for thyroid cancer.

Practitioners should consider that GLP-1RAs may not significantly increase thyroid cancer risk based on current evidence.

GLP-1RAs may have little or no effect on pancreatic cancer risk.

Practitioners should be aware that GLP-1RAs may not significantly increase pancreatic cancer risk.

There is no clear evidence that GLP-1RAs and dual GLP-1/GIPRA enhance cardiorespiratory fitness (CRF).

Practitioners should be cautious in expecting improvements in CRF from these therapies.

Cardiovascular-Renal-Hepatic-Metabolic diseases are increasing globally, posing significant challenges for patient care and clinical research.

Healthcare providers should be aware of the increasing prevalence of these diseases.

There is no significant change in resting state functional connectivity (RSFC) after the semaglutide intervention compared to the placebo group in the investigated regions of interest (ROIs).

Practitioners can consider that semaglutide does not significantly alter RSFC related to suicidal ideation and behavior in this population.

The change in RSFC between visits did not differ significantly between the groups.

This indicates that semaglutide does not lead to significant changes in RSFC over the study period compared to placebo.

There were no effects on diet quality for the 'tax' and 'healthier substitute offers.'

Strategies such as taxing unhealthy foods and offering healthier substitutes may not improve diet quality.

Recent innovations in obesity diagnosis include bioelectrical impedance analysis (BIA) and dual-energy X-ray absorptiometry (DXA) scans, alongside emerging biomarkers from 'omics' technologies.

Healthcare practitioners should consider incorporating BIA and DXA scans for more accurate obesity diagnosis.

OXT/GLP-1 co-administration increases c-Fos expression in the PVN and supraoptic nucleus.

Increased neuronal activation in specific brain regions may underlie the effects on food intake and body weight.

Mendelian randomisation did not find evidence that genetically proxied GLP-1RA increased suicide attempts in a general population cohort.

There is no genetic evidence to support an association between GLP-1RA and increased suicide attempts, suggesting safety in this regard.

There is a general recommendation against the use of non–FDA‐approved compounded incretin analogs.

Clinicians should be cautious and consider FDA approval status when prescribing incretin analogs.

Artificial intelligence (AI) is a pivotal tool in drug discovery for developing next-generation anti-obesity therapeutics.

Practitioners should consider integrating AI tools in their drug discovery processes for obesity treatments.

Approximately 10% of obesity-related glomerulopathy (ORG) patients progress to end stage renal disease 6.2 years after diagnosis.

Healthcare providers should monitor ORG patients closely for progression to end stage renal disease.

The pathogenesis of obesity-related glomerulopathy is complex, involving multiple factors.

Recognizing the complexity of ORG can guide more targeted therapeutic approaches.

Variant screening of PYY 3–36 led to the development of highly selective long-acting analogs against the Y 2 receptor.

This suggests potential for new treatments targeting the Y 2 receptor in diabetes.

The long-acting PYY analogs improved glucose metabolism in diabetic db/db mice.

Indicates potential for improved glucose control in diabetic patients.

Amylin and salmon calcitonin target distinct neurons in various brain regions.

Insights into neural targeting can inform obesity treatment strategies.

The internet-based marketing of plant-based formulations for enhancing metabolism has surged.

Practitioners should be aware of the growing trend in plant-based metabolism enhancers in the market.

Factors affecting the feasibility of nutrition research in post-ICU patients were identified, including slow patient recruitment rates, low adherence to the intervention, and the inability to complete outcome assessments.

Understanding these feasibility challenges can help improve future nutrition intervention studies.